Multi-Chiral Centre Pharmaceutical Profiling
Researchers have developed a new method of profiling compounds with multiple chiral centres using a LC–mLC approach.
coreDESIGN/stock.adobe.com
Researchers from Genentech Inc., have developed a new method of profiling compounds with multiple chiral centres using a two dimensional multicolumn liquid chromatographic (LC–mLC) approach (1).
A vast increase in drug candidates with multiple chiral centers is posing a significant challenge to analysts with the traditional chiral high performance liquid chromatography (HPLC) methods requiring a gruelling development process and still not guaranteeing a sufficient resolution for all stereoisomers. However, the precise and accurate analysis of all stereoisomers is essential as despite having the same chemical composition and connectivity, chiral stereoisomers can present vastly different pharmacological properties such as increased toxicity, differing pharmacokinetics, or even a different metabolic process. It is therefore essential that all stereoisomers of a drug compound are analysed and controlled to ensure the safety of those taking the medicines. To address this issue, researchers developed a LC–mLC 2D-LC approach which used multiple chiral stationary phases and mobile phases in the second dimension to resolve stereoisomers of compounds with multiple chiral centers and the related achiral impurities. The first dimension consists of a short achiral HPLC method to separate diastereomers and other achiral impurities, and the second dimension enables different chiral columns and different mobile phases to be used on each coeluted peak from the first dimension for maximum resolution. Essentially breaking down the complex multiple-chiral-center separations into simple individual separations.
The method was successfully employed to separate eight stereoisomers of a pharmaceutical compound with three chiral centers with a total method development time of around two hours and an analysis time of 24 min, which include column equilibration time.
References
- Lin et al., J. Chroma. A. 1620, 460987 (2020).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
